Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07027111 · ClinicalTrials.gov registry record · Phase 2
Safety, Tolerability, and Efficacy of NVG-2089 in Participants With CIDP
A Phase 2 study of Chronic Inflammatory Demyelinating Polyneuropathy, sponsored by Nuvig Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT07027111 is a Phase 2 study of Chronic Inflammatory Demyelinating Polyneuropathy that is actively recruiting participants, run by Nuvig Therapeutics. The registered enrollment target is 60 participants, below the 155-participant average among 11 other Chronic Inflammatory Demyelinating Polyneuropathy trials with a reported enrollment target (61% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07027111, a Phase 2 study of Chronic Inflammatory Demyelinating Polyneuropathy, is actively recruiting participants, sponsored by Nuvig Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to evaluate the safety of NVG-2089 and to evaluate how well patients respond to this investigational treatment. NVG-2089 is a new drug that is being developed for treating patients with CIDP. NVG-2089 is designed to mimic the effects of a protein called IVIg. NVG-2089 is designed to potentially help the immune system by attaching (binding) to certain receptors in the body and activating them, which helps reduce inflammation and supports how the immune system works.
Conditions Studied
Interventions
- DRUG NVG-2089
Study Locations (1)
Texas
- Nuvig Site - Denton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2025-04-25 |
| Est. Completion | 2028-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07027111
The ClinicalTrials.gov registry entry for NCT07027111 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 155-participant average among 11 other Chronic Inflammatory Demyelinating Polyneuropathy trials with a reported enrollment target (61% lower). The listed sponsor is Nuvig Therapeutics, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Inflammatory Demyelinating Polyneuropathy appearing as the primary indexed condition, and to 1 intervention - of which NVG-2089 is the first listed.
NCT07027111 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT07027111 about?
NCT07027111 is a clinical study titled "Safety, Tolerability, and Efficacy of NVG-2089 in Participants With CIDP". The purpose of the study is to evaluate the safety of NVG-2089 and to evaluate how well patients respond to this investigational treatment. NVG-2089 is a new drug that is being developed for treating patients with CIDP. NVG-2089 is designed to mimic the effects of a protein called IVIg. NVG-2089 is ...
What is the current status of trial NCT07027111?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2025-04-25. Estimated completion is 2028-06-30.
What conditions does trial NCT07027111 study?
This clinical trial studies the following conditions: Chronic Inflammatory Demyelinating Polyneuropathy.
What interventions are being tested in trial NCT07027111?
The interventions under investigation include: NVG-2089 (DRUG).
Who is sponsoring clinical trial NCT07027111?
This trial is sponsored by Nuvig Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07027111 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Inflammatory Demyelinating Polyneuropathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
IMVT-1402 in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
RECRUITING · Phase 2
-
To Assess Efficacy and Safety of Batoclimab in Adult Participants With Active CIDP
ACTIVE NOT RECRUITING · Phase 2
-
A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)
RECRUITING · Phase 3
-
A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP
RECRUITING · Phase 3
-
IVIG vs SCIG in CIDP
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.